Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015

Journal of Clinical and Experimental Hepatology

Volumn 5, Issue 3, 2015, Pages 221-238

  Puri, Pankaj ^a   Anand, Anil C ^b   Saraswat, Vivek A ^c   Acharya, Subrat K ^d   Dhiman, Radha K ^e   Sarin, Shiv K ^f   Singh, Shivaram P ^g   Chawla, Yogesh K ^e   Aggarwal, Rakesh ^c   Amarapurkar, Deepak ^h   Arora, Anil ⁱ   Dixit, Vinod K ^j   Sood, Ajit ^k   Shah, Samir ^l   Duseja, Ajay ^e   Kapoor, Dharmesh ^m   Shalimar, ⁿ   Madan, Kaushal ⁿ   Pande, Gaurav ^c   Nagral, Aabha ^o   Kar, Premashis ^p   Koshy, Abraham ^q   Puri, Amarender S ^r   Eapen, C E ^s   Thareja, Sandeep ^t   more..

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b INDRAPRASTHA APOLLO HOSPITAL   (India)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^g SCB MEDICAL COLLEGE   (India)

^h BOMBAY HOSPITAL   (India)

ⁱ SIR GANGA RAM HOSPITAL   (India)

^j BANARAS HINDU UNIVERSITY   (India)

^k DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^l Global Hospital   (India)

^m Global Hospital   (India)

ⁿ ARTEMIS HOSPITAL   (India)

^o JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^p MAULANA AZAD MEDICAL COLLEGE   (India)

^q Lakeshore Hospital   (India)

^r G B PANT HOSPITAL   (India)

^s CHRISTIAN MEDICAL COLLEGE   (India)

^t ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

more..

Author keywords

Antiviral therapy; Chronic hepatitis; HCV; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; CARBAMAZEPINE; DACLATASVIR; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIGEN; HYPERICUM PERFORATUM EXTRACT; INTERLEUKIN 28B; LEDIPASVIR; OXCARBAZEPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENOBARBITAL; PHENYTOIN; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TIPRANAVIR; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEADACHE; HEARING DISORDER; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATOMEGALY; HUMAN; HYPERTENSION; INCIDENCE; INDIA; INDIAN NATIONAL ASSOCIATION FOR STUDY OF THE LIVER; INJECTION SITE REACTION; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL LUNG DISEASE; IRRITABILITY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID VIROLOGIC RESPONSE; RECURRENT DISEASE; RELAPSE; RETINA DISEASE; REVIEW; RISK FACTOR; SEROCONVERSION; SLEEP DISORDER; STEATOSIS; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; THYROID FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER;

EID: 84945557032     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2015.09.002     Document Type: Review

References (81)

1. AASLD/IDSA Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015, 62:932-954.
2. Anon Guidelines for the screening care and treatment of persons with hepatitis infection 2014, WHO, Geneva.
3. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 63:199-236.
4. Myers R.P., Shah H., Burak K.W., Cooper C., Feld J.J. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015, 29:19-34.
5. Berden F.A.C., Kievit W., Baak L.C. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med 2014, 72:388-400.
6. NICE technology appraisal guidance 330 Sofosbuvir for treating chronic hepatitis C 2015, [accessed 27.08.15]. http://www.nice.org.uk/guidance/ta330.
7. Puri P., Anand A.C., Saraswat V.A., et al. Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India. J Clin Exp Hepatol 2014, 4:104-114.
8. Puri P., Anand A.C., Saraswat V.A., et al. Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part II: INASL recommendations for management of HCV in India. J Clin Exp Hepatol 2014, 4:117-140.
9. Ford N., Swan T., Beyer P., Hirnschall G., Easterbrook P., Wiktor S. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol 2014, 61:S132-S138.
10. Hatzakis A., Chulanov V., Gadano A.C., et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat 2015, 22(suppl. S1):26-45.
11. Wedemeyer H., Dore G.J., Ward J.W. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 2015, 22(suppl. S1):1-5.
12. Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144:1450-1455.
13. Lawitz E., Gane E., Lalezari J., Hyland R., Ma J., Symonds W. High concordance of SVR4, SVR12 and SVR24 in patients with HCV infection who have received treatment with sofosbuvir. J Hepatol 2013, 58:S229-S407. Abstract 848.
14. Tanaka E., Ohue C., Aoyagi K., et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000, 32:388-393.
15. Chakravarti A., Chauhan M.S., Dogra G., Banerjee S. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?. Braz J Infect Dis 2013, 17(3):369-374.
16. Cresswell F.V., Fisher M., Hughes D.J., Shaw S.G., Homer G., Hassan-Ibrahim M.O. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis 2015, 60:263-266.
17. Moini M., Ziyaeyan M., Aghaei S., et al. Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two Methods; HCV core antigen and polymerase chain reaction. Hepat Mon 2013, 13(6):e9147.
18. Mixson-Hayden T., Dawson G.J., Teshale E., et al. Performance of architect HCV core antigen test with specimens from US plasma donors and injecting drug users. J Clin Virol 2015, 66:15-18.
19. Vermehren J., Susser S., Berger A., et al. Clinical utility of the architect HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012, 55:17-22.
20. Daniel H.D.J., Vivekanandan P., Raghuraman S., Sridharan G., Chandy G.M., Abraham P. Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection. Int J Med Microbiol 2007, 25:37-42.
21. Tillmann H.L. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol 2014, 20(22):6701-6706.
22. Reyes-Mendez M.A., Juarez-Figueroa L., Iracheta-Hernandez P., Medina-Islas Y., Ruiz-Gonzalez V. Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test. Ann Hepatol 2014, 13:337-342.
23. Sivaprasad S., Rao P.N., Gupta R., Aswini K., Reddy D.N. The distribution of genotype and allelic frequency of IL28B gene polymorphisms in Andhra Pradesh, India. J Clin Exp Hepatol 2012, 2:112-115.
24. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
25. EASL-ALEH Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015, 63:237-264.
26. Bonder A., Tapper E.B., Afdhal N.H. Contemporary assessment of hepatic fibrosis. Clin Liver Dis 2015, 19:123-134.
27. Messina J.P., Humphreys I., Flaxman A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61:77-87.
28. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
29. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
30. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370:1993-2001.
31. Foster G.R., Pianko S., Brown A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection. Gastroenterology 2015, 10.1053/j.gastro.2015.07.043.
32. Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
33. Lawitz E., Poordad F., Brainard D.M., et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013, 58:1380A.
34. Esteban R., Nyberg L., Lalezari J., et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol 2014, 60:S4.
35. Kowdley K.V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, 381:2100-2107.
36. Osinusi A., Meissner E.G., Lee Y.J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. J Am Med Assoc 2013, 310:804-811.
37. Lalezari J.P., Nelson D.R., Hyland R.H., et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol 2013, 58:S346.
38. Pearlman B.L., Ehleben C., Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015, 148:762-770.
39. Mishra P., Florian J., Qi K., et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology 2014, 147:1196-1200.
40. Jensen D.M., O'Leary J.G., Pockros P.J., et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience in a diverse, longitudinal observational cohort. Hepatology 2014, 60:219A.
41. Dieterich D., Bacon B.R., Flamm S.L., et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014, 60:220A.
42. Ruane P.J., Ain D., Stryker R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015, 62:1040-1046.
43. Doss W., Shiha G., Hassany M., et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015, 63:581-585.
44. Sood A., Midha V., Sood N., Kaur A., Puri S. Response to antiviral treatment in patients with chronic hepatitis C with persistently normal liver enzymes. Indian J Gastroenterol 2010, 29(2):90-91.
45. David J., Rajasekar A., Daniel H.D.D., et al. Infection with hepatitis C virus genotype 3-experience of a tertiary health care center in south India. Indian J Med Microbiol 2010, 28:155-157.
46. Tohra S.K., Taneja S., Ghosh S., et al. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and RBV in patients with genotype 3 chronic hepatitis C. Dig Dis Sci 2011, 56:2449-2455.
47. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
48. Curry M.P., Forns X., Chung R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015, 148:100-107.
49. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
50. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
51. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
52. Manns M., Pol S., Jacobson I., et al. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results. J Hepatol 2014, 60:S524.
53. Afdhal N., Everson G., Calleja J.L., et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014, 60(suppl. 1):S28.
54. Akhtar E., Manne V., Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2015, 35:30-36.
55. Ruiz I., Feray C., Pawlotsky J.M., Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015, 21:408-409.
56. Flamm S.L., Everson G.T., Charlton M., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014, 60(suppl. 1):320A.
57. Samuel D., Bizollon T., Feray C., et al. Interferon-alpha 2b plus RBV in patients with chronic hepatitis C after liver transplantation: a randomized controlled study. Gastroenterology 2003, 124:642-650.
58. Carrion J.A., Navasa M., Garcia-Retortillo M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
59. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with RBV. J Hepatol 2008, 49:274-287.
60. Berenguer M., Palau A., Aguilera V., Rayon J.M., Juan F.S., Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008, 8:679-687.
61. Charlton M., Gane E., Manns M.P. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015, 148:108-117.
62. Forns X., Charlton M., Denning J., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015, [in press]. 10.1002/hep.27681.
63. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C infection: a meta-analysis. Clin Infect Dis 2001, 33(4):562-569.
64. Soriano V., Puoti M., Garcia-Gascó P., et al. Antiretroviral drugs and liver injury. AIDS 2008, 22:1-13.
65. Opravil M., Sasadeusz J., Cooper D.A., et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40kD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47:36-49.
66. Soriano V., Sulkowski M., Bergin C., et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
67. Molina J.M., Orkin C., Iser D.M., et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015, 385:1098-1106.
68. Labarga P., Fernandez-Montero J.V., de Mendoza C., Barreiro P., Pinilla J., Soriano V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV coinfected patients. Antivir Ther 2015, 20:329-334.
69. Saravanan S., Velu V., Nandakumar S., et al. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease. J Microbiol Immunol Infect 2009, 42:122-128.
70. Chakravarti A., Verma V., Jain M., Kar P. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital. Trop Gastroenterol 2005, 26:183-187.
71. Xess A., Kumar M., Minz S., Sharma H.P., Shahi S.K. Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol 2001, 44:253-255.
72. Jamma S., Hussain G., Lau T.Y. Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony. Curr Hepat Rep 2010, 9:260-269.
73. Liu J.Y., Sheng Y.J., Hu H.D., et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012, 9:186-193.
74. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347-354.
75. Potthoff A., Wedemeyer H., Boecher W.O., et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV coinfection. J Hepatol 2008, 49:688-694.
76. Tan A.C., Brouwer J.T., Glue P., et al. Safety of interferon and RBV therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001, 16:193-195.
77. Mousa D.H., Abdalla A.H., Al-Shoail G., Al-Sulaiman M.H., Al-Hawas F.A., Al-Khader A.A. Alpha-interferon with RBV in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004, 36:1831-1834.
78. Bruchfeld A., Lindahl K., Reichard O., Carlsson T., Schvarcz R. Pegylated interferon and RBV treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006, 13:316-321.
79. Rendina M., Schena A., Castellaneta N.M., et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus RBV in haemodialysed patients awaiting renal transplant. J Hepatol 2007, 46:768-774.
80. Amarapurkar D.N., Patel N.D., Kirpalani A.L. Monotherapy with peginterferon alpha-2b {12kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol 2007, 28:16-18.
81. Duseja A., Choudhary N., Gupta S., Dhiman R.K., Chawla Y., Sakhuja V. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol 2012, 33:189-192.